|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
J Schuepbach, S Arrenbrecht and C Sauter
Twenty-four acute myelogenous leukemia (AML) patients in first clinical
remission received, as a part of their maintenance therapy, repeated
injections of viral oncolysate (i.e., avian influenza virus-infected,
formalin-inactivated, allogeneic leukemia cells). The anti-oncolysate-
virus antibody responses after a single injection, tested by a
radioimmunoassay, were in inverse correlation to the remission duration (p
less than or equal to 0.01). The 25% of patients with the lowest responses
had a median remission duration of more than 36 mo, with no relapses within
the first 18 mo. In contrast, the 75% of patients with higher responses had
a median remission time of less than 5 mo, and more than 80% relapsed
within 18 mo. Despite the small number of patients, these differences are
highly significant (p less than or equal to 0.001). Immunization of
remission AML patients with viral oncolysate provides a powerful prognostic
test. Most early relapses can be predicted, with a modest rate of
false-positive and false-negative predictions.
This article has been cited by other articles:
| |||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 1983 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
